Abstract: A medicated patch for extracting bee/wasp sting toxins from the human skin includes a flexible substrate layer that has a planar adhesive surface and an annular shape. An annular receptacle is centrally registered on the adhesive surface and is permanently affixed to the substrate layer. A poultice is nested on the receptacle and protrudes upwardly and away from the substrate layer such that the poultice becomes effectively intercalated between the human body surface and the substrate layer when a user affixes the medicated patch onto the human body surface. The poultice is housed in an inactive and dry state during pre-application conditions and is adaptable to an active and hydrated state during application procedures such that the poultice can effectively extract toxins from the human body surface.

Abstract: Compositions and methods for treating osteoporosis, the formation of osteoeclasts, and/or for the suppression of decreasing spongy bone density. Example methods include administering Cordyceps sinensis or its processed product.

Abstract: Methods and compositions comprising marine botanicals for treating aged, mature, nutritionally-compromised, or environmentally-damaged skin. These methods and compositions provide improvements in the skin's visual appearance, physiological functions, clinical properties, and biophysical properties.

Abstract: A process for enhancing theanine extraction from plant material through a series of extraction, adsorption and filtration steps. More specifically, disclosed is a process for isolating theanine from a plant material, which includes the steps of: a) contacting the plant material with a solvent to obtain an extract comprising theanine; b) contacting the theanine extract with an adsorbent to obtain a theanine-containing eluate; and c) subjecting the theanine eluate to a filtration step to obtain a theanine-rich extract.

Abstract: A nutritional, cosmetic and pharmaceutical compositions containing active ingredients from the liquid endosperm of fresh green coconuts, and a method for obtaining the active ingredients.

Abstract: A pharmaceutical composition comprising an effective amount of an extract or lyophilized extract or at least one bioactive fraction obtained from the plant Woodfordia fruticosa along with one or more pharmaceutically acceptable additives/carriers for treating ulcer caused by the conditions such as stress induced ulcer, peptic ulcer, cold restraint induced ulcer, drug induced ulcer and acid induced ulcer, also used as specific inhibitor of gastric H+, K+-ATPase and anti-Helicobacter pylori activity.

Abstract: A hair growth inhibitor contains, as an active ingredient, at least one herb selected from the group consisting of phellodendron bark, houttuynia, rice bran, mulberry tree bark, Japanese coptis, thyme, peach seed, nettle, calendula, wild rose and balm mint or the extract thereof and various skin external application compositions such as cosmetic compositions to be used on the outer skin is prepared by mixing these active ingredients with other aqueous phase ingredients and oil phase ingredients according to conventional-methods.

Abstract: An adjustable resistance valve for a cerebrospinal fluid shunt system includes an actuator for allowing the selection of the resistance to flow of the valve, a device for selecting at least one passage traversing across the valve, and a resistance system. The resistance system includes a set of passages each defining a different resistance to flow. The passages are disposed in a circle facing the selecting device such as to guide the flow of the cerebrospinal fluid traversing the passage of the selecting device through the selected passage of the resistance system. The actuator enables one to change the relative position of the selecting device with respect to the resistance system by a rotational movement to select the desired resistance of the valve.

Abstract: The present invention relates to a method of preventing and/or treating diabetes type 2, also, it relates to a method of augmenting Glut4 phosphorylation and Glut4 translocation to a target cell membrane to enhance insulin signal in a signal transduction pathway; further, it relates to a simplified and inexpensive process of obtaining extract and thereafter selectively, its active n-butanol fraction and active molecule Lupinoside PA (LPA4), useful in preventing and/or treating diabetes type 2; and lastly, a pharmaceutical composition thereof.

Abstract: An extract of the Minari plant containing a component which prevents cancer and cancer metastasis. A Minari extract which is useful for the prevention of cancer and cancer metastasis induced by urethane (EC (ethylcarbamate)), which is a carcinogen present in fermented foods or alcoholic beverages, or by NNK[{(4-N-methyl-N-nitrosoamino)-1-(3-pyridyl)-1-buta none)}], which is a carcinogen present in cigarette smoke.

Abstract: A method for treating a disease selected from diabetes mellitus and atherosclerosis, and a method for reducing triglycerides and/or increasing HDL cholesterol levels in the plasma of a subject. The method comprises administrating. to a subject an effective amount of crude Dunaliella powder, optionally together with an activator of nuclear receptors.

Abstract: The invention relates to a method for treatment of chronic myelogenous leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), prostate cancer and ?-globin disorders such as sickle cell anemia and ?-thalassemia, comprising administration of a mycelium extract from at least one higher Basidiomycetes medicinal mushroom selected from the group consisting of Ganoderma adspersum, Hypsizygus ulmarium, Kuehneromyces mutabilis, Omphalotus olearius, Panus conchatus, Piptoporus betulinus, Pleurotus eryngii, and Trametes zonata.

Abstract: Methods for the isolation and identification of a toxicant in a sample are disclosed. Luminescent biological agents (i.e., bacteria) having sensitivity to a toxicant or an isolatable component in a sample are used to provide visually discernable zones of luminescent inhibition in the presence of a toxicant (or) in the presence of an isolatable sample component as separated by paper or thin layer chromatography. Kits for use in conjunction with the identification of a toxicant in a sample are also described, which include a luminescent biological reagent as the visualizing agent. Particular examples of luminescent bacterial agents useful in the practice of the present invention include Photobacterium leoganthi, Photobacterium phosphoreum, Vibrio fischeri, Vibrio harveyi a luminescent fungi, a luminescent fish extract, a luminescent dinoflagellate and fluorescent microorganisms, such as Cypridina.

Abstract: Provided is a use for Bowman Birk Inhibitor (BBI), as administered in Bowman Birk Inhibitor Concentrate (BBIC), for the treatment of autoimmune diseases in a patient, wherein the disease is characterized by chronic inflammation, such as rheumatoid arthritis; and more particularly for the treatment of those diseases that are characterized by chronic neuroinflammation and/or demyelination, such as Multiple Sclerosis (MS) and Guillain Barre Syndrome (GBS). In addition, the present invention provides methods for using BBI/BBIC to reduce, inhibit, suppress or prevent the chronic inflammation in such patients; and more particularly, to reduce, inhibit, suppress or prevent the chronic neuroinflammation and demyelination that occurs when the patient's nerve tissues are affected by the disease.

Abstract: A skin whitening composition includes an extract of asparagus obtained by sequentially exposing the asparagus to two or more solvents of varying solvent strengths. The root and shoot portions of the asparagus can be separately used to obtain the extract. The composition can be topically applied to the human skin and can further include one or more cosmetically acceptable ingredients. A method of suppressing melanogenesis includes topically applying to the skin a composition comprising an extract of asparagus obtained by sequentially exposing the asparagus to two or more solvents of varying solvent strengths.

Abstract: Compositions and methods for preventing and treating disease are provided. The compositions are extracts of black tea that include a mixture of theaflavin-3-gallate and theaflavin-3?-gallate.

Abstract: Homeopathic formulations (a) comprising tinctures and/or diluted extracts preferably subjected to potentization of at least 8 or 9 herbs selected from Bellis Perennis, Calendula Officinalis, Hamamelis Virginiana, Arnica Montana, Hypericum Perforatum, Aconitum Napellus, Ledum Palustre, Bryonia Alba and Ruta Graveolens; or (b) consisting of, as active ingredients, tinctures and/or diluted extracts subjected to potentization of 5, 6 or 7 herbs selected from Bellis Perennis, Calendula Officinalis, Hamamelis Virginiana, Arnica Montana, Hypericum Perforatum, Aconitum Napellus, Ledum Palustre, Bryonia Alba and Ruta Graveolens. The potentized homeopathics are in a penetrating base, preferably clear gel base. The homeopathic formulations are highly effective in treating or relieving pain and inflammation. Also, a method of treating or relieving pain and inflammation by administering any of the homeopathic formulations of the invention to a subject, preferably a subject in need of such treatment or relief.

Abstract: Disclosed are gel-based cosmetic and wound-healing formulations, methods for making said formulations, and a method for simultaneously treating and concealing injuries to human skin. In one exemplary embodiment, the cosmetic and wound-healing formulation comprises live yeast cell extract, pigment, and a gel.

Abstract: The present invention relates generally to the use of botanical extract compositions, which contain ingredients with self-preserving properties for use in cosmetic or dermatological compositions.

Abstract: treating method for hair growth inhibition, which comprises administering (A) the extract of a plant of the family Juniperus or a malt. In addition, the present invention relates to a dermatologic composition for external use, which comprises (B) an elastase inhibitor or neutral endopeptidase inhibitor, and the above-described component (A) and/or (C) at least one proteolytic enzyme selected from the group consisting of papain, trypsin, chymotrypsin, pepsin, bromelain, ficin and pancreatin.